Pricing Availability   Qty
Description: NMDA partial agonist; acts at the glycine site
Alternative Names: Rapastinel
Purity: ≥95% (HPLC)
Citations (1)
Literature (5)

Biological Activity for GLYX 13

GLYX 13 is a NMDA receptor partial agonist that acts at the glycine site. Simultaneously acts as a promoter of the induction of long-term potentiation (LTP) and as a suppressor of long-term depression (LTD). Also promotes VGF and BDNF release and increases ERK/mTOR signaling. Exhibits nootropic, neuroprotective and antinociceptive activity, and enhances learning, memory and cognition in vivo. Brain penetrant.

Technical Data for GLYX 13

M. Wt 413.47
Formula C18H31N5O6
Sequence TPPT

(Modifications: Thr-4 = C-terminal amide)

Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 117928-94-6
PubChem ID 14539800
Smiles [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for GLYX 13

Solubility Soluble to 2 mg/ml in water

Product Datasheets for GLYX 13

Certificate of Analysis / Product Datasheet
Select another batch:

References for GLYX 13

References are publications that support the biological activity of the product.

Moskal et al (2005) GLYX-13: A monoclonal antibody-derived peptide that acts as an N-MthD.-aspartate receptor modulator. Neuropharmacology 49 1077 PMID: 16051282

Zhang et al (2008) A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. 55 1238 PMID: 18796308

Wood et al (2008) Antinociceptive action of GLYX-13: a N-MthD.-aspartate receptor glycine site partial agonist. Neuroreport. 19 1059 PMID: 18580579

Burgdorf et al (2009) The N-MthD.-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol.Aging 32 698 PMID: 19446371

Shen et al (2022) ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice. Transl.Psychiatry 12 522 PMID: 36550125

If you know of a relevant reference for GLYX 13, please let us know.

View Related Products by Product Action

View all NMDA Receptor Agonists

Keywords: GLYX 13, GLYX 13 supplier, NMDA, receptor, partial, agonists, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, GLYX13, psychoplastogen, Rapastinel, 3406, Tocris Bioscience

1 Citation for GLYX 13

Citations are publications that use Tocris products. Selected citations for GLYX 13 include:

Shen et al (2022) ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice. Transl.Psychiatry 12 522 PMID: 36550125

Do you know of a great paper that uses GLYX 13 from Tocris? Please let us know.

Reviews for GLYX 13

There are currently no reviews for this product. Be the first to review GLYX 13 and earn rewards!

Have you used GLYX 13?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.